- Home
- EOI vs AUTL Comparison
EOI vs AUTL Comparison
Compare EOI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EOI
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EOI | AUTL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.7M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EOI | AUTL |
|---|---|---|
| Price | $20.51 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 83.6K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,128,000.00 |
| Revenue This Year | N/A | $669.49 |
| Revenue Next Year | N/A | $91.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $14.36 | $1.11 |
| 52 Week High | $18.88 | $2.80 |
Technical Indicators
Market Signals| Indicator | EOI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 63.25 | 69.18 |
| Support Level | $20.14 | $1.63 |
| Resistance Level | $20.62 | $1.79 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 88.70 | 96.85 |
Price Performance
Historical ComparisonAbout EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.